4.7 Article

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents

Related references

Note: Only part of the references are listed.
Review Oncology

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Yuan Yuan et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)

Article Biochemistry & Molecular Biology

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

M. H. Aziz et al.

ONCOGENE (2011)

Review Pharmacology & Pharmacy

Reactivation of p53: from peptides to small molecules

Christopher J. Brown et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2011)

Article Pharmacology & Pharmacy

DNA damage response to the Mdm2 inhibitor Nutlin-3

Rajeev Verma et al.

BIOCHEMICAL PHARMACOLOGY (2010)

Article Pharmacology & Pharmacy

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines

Martin Michaelis et al.

BIOCHEMICAL PHARMACOLOGY (2010)

Article Biochemistry & Molecular Biology

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors

N Issaeva et al.

NATURE MEDICINE (2004)

Article Multidisciplinary Sciences

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

S Kato et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)